Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $70M (up 24.1% year over year) with net income of −$23M.
Q3 2026 key financials · XBRL
- Revenue
- $70M
- +24.1% YoY · +38.2% QoQ
- Net income
- −$23M
- +0.1% YoY · +63.9% QoQ
- Operating margin
- -33.7%
- EPS (diluted)
- −$0.37
- +5.1% YoY · +64.4% QoQ
Source: XBRL data from the Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 10-Q on SEC EDGAR. USD.
Vanda Pharmaceuticals Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $69.8M, up 24% YoY from $56.3M
- Fanapt best performer, sales $38.8M, up 24% YoY; NEREUS $1.6M launch revenue
- Gross margin 94.0% vs 94.7% YoY, based on revenue and cost of goods sold
- Cash, equivalents and securities $140.5M vs $263.8M; operating cash outflow nine months $109.7M
- Outlook: BYSANTI launch expected Q4 2026; HETLIOZ sales may decline significantly amid generic competition
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward business risk: factors could materially adversely affect operations, financial condition, and common-stock price
- Filing identifies no newly triggered regulatory, legal, operational, competitive, market, or financial risk changes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vanda Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.